MRK · CIK 0000310158 · operating
Merck & Co. operates as a diversified healthcare manufacturer with a global presence. The company develops and commercializes pharmaceutical products addressing oncology, infectious disease, cardiovascular disease, diabetes, and immunology. Its human health pharmaceutical portfolio includes established brands such as Keytruda (a PD-1 inhibitor used in cancer treatment), Gardasil (human papillomavirus vaccine), Januvia (diabetes treatment), and Lagevrio (antiviral for COVID-19), among others.
The company maintains a substantial veterinary business segment serving livestock and companion animal markets. This division manufactures vaccines, therapeutics, and health management solutions across cattle, swine, and poultry applications, as well as products for dogs and cats. The veterinary portfolio includes brands such as Bovilis, Bravecto, and Sentinel Spectrum.
Merck was incorporated in New Jersey and is headquartered in Rahway, New Jersey. The company trades on the NYSE with a market capitalization of approximately $304 billion. Its operations span worldwide markets with an extensive research and development network. The company maintains multiple collaborative agreements with pharmaceutical and biotechnology partners including AstraZeneca, Daiichi Sankyo, Eisai, Moderna, and others to expand its development pipeline and commercialization capabilities.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $7.28 | $7.30 | +8.0% | |
| 2024 | $6.74 | $6.76 | +4714.3% | |
| 2023 | $0.14 | $0.14 | -97.5% | |
| 2022 | $5.71 | $5.73 | +11.1% | |
| 2021 | $5.14 | $5.16 | +84.9% | |
| 2020 | $2.78 | $2.79 | -27.0% | |
| 2019 | $3.81 | $3.84 | +64.2% | |
| 2018 | $2.32 | $2.34 | +166.7% | |
| 2017 | $0.87 | $0.88 | -38.3% | |
| 2016 | $1.41 | $1.42 | -9.6% | |
| 2015 | $1.56 | $1.58 | -61.7% | |
| 2014 | $4.07 | $4.12 | +176.9% | |
| 2013 | $1.47 | $1.49 | -26.5% | |
| 2012 | $2.00 | $2.03 | -1.0% | |
| 2011 | $2.02 | $2.04 | +621.4% | |
| 2010 | $0.28 | $0.28 | -95.0% | |
| 2009 | $5.65 | $5.67 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-24 | 0000310158-26-000063 | SEC ↗ |
| 2024-12-31 | 2025-02-25 | 0001628280-25-007732 | SEC ↗ |
| 2023-12-31 | 2024-02-26 | 0001628280-24-006850 | SEC ↗ |
| 2022-12-31 | 2023-02-24 | 0001628280-23-005061 | SEC ↗ |
| 2021-12-31 | 2022-02-25 | 0000310158-22-000003 | SEC ↗ |
| 2020-12-31 | 2021-02-25 | 0000310158-21-000004 | SEC ↗ |
| 2019-12-31 | 2020-02-26 | 0000310158-20-000005 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0000310158-19-000014 | SEC ↗ |
| 2017-12-31 | 2018-02-27 | 0000310158-18-000005 | SEC ↗ |